Effects of human T-lymphotropic virus type II on human immunodeficiency virus type 1 phenotypic evolution

Archives of Virology

Volumn 146, Issue 8, 2001, Pages 1617-1622

  Guenthner, P C ^a   Hershow, R C ^b   Lal, R B ^a   Dezzutti, C S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T LYMPHOTROPIC VIRUS II; RANTES; VIRUS COINFECTION; VIRUS INFECTION; VIRUS RECEPTOR;

CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CC; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; PHENOTYPE; RECEPTORS, CCR5;

EID: 0034867273     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007050170083     Document Type: Article

References (18)

1. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
2. Seroprevalence of human T cell lymphotropic virus type II infection, with or without human immunodeficiency virus type 1 coinfection, among US intravenous drug users
3. HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1α
4. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ cells
5. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals
6. Human T-cell leukemia virus type II infection among high risk groups and its influence on HIV-1 disease progression
7. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users
8. In vivo cellular tropism of human T cell leukemia virus type II
9. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases
10. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis
11. In vivo cellular tropism of human T-lymphotropic virus type II is not restricted to CD8+ cells
12. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
13. HTLV-II does not adversely affect the natural history of HIV-1 infection in intravenous drug users
14. Factors secreted by human T lymphotropic virus type I (HTLV-I)-infected cells can enhance or inhibit replication of HIV-1 in HTLV-I-uninfected cells: Implications for in vivo coinfection with HTLV-I and HIV-1
15. HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users
16. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture
17. Molecular cloning, expression, and characterization of an HTLV-II envelope glycoprotein: HIV-1 expression is permissive for HTLV-II-induced cell fusion
18. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression